Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19

Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis. Retrospective...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease Vol. 53; no. 5; pp. 525 - 533
Main Authors: Campos-Murguía, Alejandro, Román-Calleja, Berenice Monserrat, Toledo-Coronado, Israel Vicente, González-Regueiro, José Alberto, Solís-Ortega, Alberto Adrián, Kúsulas-Delint, Deyanira, Cruz-Contreras, Mariana, Cruz-Yedra, Nabila, Cubero, Francisco Javier, Nevzorova, Yulia Alexandrowna, Martínez-Cabrera, Carlos Fernando, Moreno-Guillén, Paulina, Lozano-Cruz, Oscar Arturo, Chapa-Ibargüengoitia, Mónica, Gulías-Herrero, Alfonso, Aguilar-Salinas, Carlos Alberto, Ruiz-Margáin, Astrid, Macías-Rodríguez, Ricardo Ulises
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 01.05.2021
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd
Subjects:
ISSN:1590-8658, 1878-3562, 1878-3562
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first